Document Detail

Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
MedLine Citation:
PMID:  23350856     Owner:  NLM     Status:  Publisher    
OBJECTIVE: Pioglitazone, a thiazolidinedione, was approved for treatment of Type 2 diabetes. However, several observational studies suggest an association of pioglitazone with an increased risk of bladder cancer in patients with diabetes. Therefore, we sought to perform a systematic review and meta-analysis to evaluate the magnitude of this association and the quality of the supporting evidence. RESEARCH DESIGN AND METHODS: Electronic databases were queried to identify controlled studies of pioglitazone that measured the risk of bladder cancer. RESULTS: Six studies involving 215 142 patients using pioglitazone were included, with a median period of follow-up of 44 months. The hazard of developing bladder cancer was significantly higher in patients using pioglitazone (hazard ratio 1.23; 95% CI 1.09-1.39; I(2)  = 0%) compared with control groups. The risk of bias was moderate across the six studies. Considering an incidence rate of 20.8 per 100 000 person years, the number needed to harm was five additional cases of bladder cancer per 100 000 person years. CONCLUSION: Pioglitazone use is associated with an increased risk of bladder cancer. Clinicians must consider this increased risk in the context of the baseline risk for bladder cancer of their patients, other adverse features of this medicine (e.g. weight gain, cost) and its potential anti-hyperglycaemic benefits. © 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK.
M Ferwana; B Firwana; R Hasan; M H Al-Mallah; S Kim; V M Montori; M H Murad
Related Documents :
23712946 - Prevalence and predictors of cancer specific distress in men with a family history of p...
23564936 - Cost-effectiveness and quality of life in surgeon versus general practitioner-organised...
23091106 - Risks of less common cancers in proven mutation carriers with lynch syndrome.
24699986 - Survival from anal cancer among hispanics-puerto rico, 2000-2007.
23125926 - Lung radiofrequency ablation: potential as a therapy to oligometastasis and oligorecurr...
1661196 - Immunology of hepatocellular carcinoma.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-28
Journal Detail:
Title:  Diabetic medicine : a journal of the British Diabetic Association     Volume:  -     ISSN:  1464-5491     ISO Abbreviation:  Diabet. Med.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8500858     Medline TA:  Diabet Med     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2013 The Authors. Diabetic Medicine © 2013 Diabetes UK.
National and Gulf Center for Evidence Based Health Practice, King Saud bin Abdulaziz University for Health Sciences; Family Medicine and Primary Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Actinobaculum schaalii, a commensal of the urogenital area.
Next Document:  Drug-induced liver injury in the Australian setting.